Akums Secures Patent For Room Temperature Stable Hydroxyurea Oral Suspension For Sickle Cell Disease

Akums Drugs and Pharmaceuticals, India’s largest Contract Development and Manufacturing Organisation (CDMO), has been granted a patent for its innovative Room Temperature Stable Oral Suspension of Hydroxyurea. 

The company in a press statement on Friday informed that this new formulation is designed to manage Sickle Cell Disease (SCD) and addresses key challenges in storing and distributing Hydroxyurea, especially in areas with limited access to refrigeration.

Sickle Cell Disease, a genetic blood disorder affecting millions worldwide, is prevalent in India and Africa. In India, 8.6 per cent of the population is from tribal communities, many of whom are disproportionately impacted by SCD. Traditional Hydroxyurea solutions must be stored between 2–8°C, which poses logistical challenges for distribution in remote regions. Akums’ oral suspension, which remains stable at room temperature, offers a significant improvement in accessibility for patients in these areas, particularly in tribal regions lacking cold storage.

Sanjeev Jain, Managing Director of Akums, stated, "Securing this patent marks a pivotal step in improving the lives of SCD patients, especially in India and Africa. At Akums, we remain dedicated to innovating affordable healthcare solutions that enhance patient outcomes and support the fight against rare diseases."

Sandeep Jain, Managing Director, added, "This patent reinforces our commitment to the ‘Make in India’ initiative and aligns with the Government of India’s mission to provide cost-effective, high-quality medicines. Our new formulation is a game-changer for pediatric and adolescent patients suffering from SCD, offering dose flexibility and greater accessibility, particularly in tribal areas."